An investment consortium led by Signet Healthcare Partners, Bionpharma, Inc and GMS Capital Partners has formed Pharma Nobis to acquire Fagron’s US contract manufacturing business.
An investment consortium led by Signet Healthcare Partners, Bionpharma, Inc and GMS Capital Partners has formed Pharma Nobis to acquire Fagron’s US contract manufacturing business.
This business unit, operating from a manufacturing facility in Texarkana, Texas, provides contract manufacturing and private label services for consumer healthcare companies and retailers in the United States.
Fagron will retain a 20 per cent interest in the Company. Todd Daviau, co-founder and former President & CEO of CoreRx, a leading pharmaceutical contract development and manufacturing company, was named CEO of Pharma Nobis.
Concurrent with the acquisition, the Company announced that James Gale, Dr. Theron Odlaug, Yezan Haddadin, and Andrew Pulido will join its Board of Directors, along with Todd Daviau. Dr. Odlaug is an experienced pharmaceutical executive and Signet Venture Partner. Yezan Haddadin is the CEO of GMS Capital Partners LLC. Andrew Pulido is the President of Fagron North America.
